[Form 4] Apogee Therapeutics, Inc. Insider Trading Activity
Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), reported a sale of 2,725 shares of Apogee common stock on 08/06/2025 at a reported price of $37.78 per share. The transaction is recorded on a Form 4 and was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024, a plan described in the filing as intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
The filing shows that following the reported sale Mr. Dambkowski beneficially owned 236,273 shares, held directly. No derivative transactions are reported on this Form 4 and the document is limited to the single non-derivative sale and the related ownership position.
Carl Dambkowski, Chief Medical Officer di Apogee Therapeutics (APGE), ha segnalato la vendita di 2,725 azioni ordinarie di Apogee in data 08/06/2025 al prezzo indicato di $37.78 per azione. La transazione è riportata in un Form 4 ed è stata eseguita ai sensi di un piano di negoziazione Rule 10b5-1 adottato il August 21, 2024, descritto nel documento come finalizzato a soddisfare le condizioni della difesa affermativa previste dalla Rule 10b5-1(c).
Dalla comunicazione risulta che, dopo la vendita, il sig. Dambkowski possedeva beneficiariamente 236,273 azioni, detenute direttamente. Nel Form 4 non sono segnalate operazioni su derivati: il documento si limita a questa singola vendita non derivata e alla relativa posizione di proprietà.
Carl Dambkowski, Chief Medical Officer de Apogee Therapeutics (APGE), informó la venta de 2,725 acciones ordinarias de Apogee el 08/06/2025 a un precio informado de $37.78 por acción. La operación consta en un Form 4 y se ejecutó en virtud de un plan de negociación bajo la Rule 10b5-1 adoptado el August 21, 2024, descrito en la presentación como destinado a satisfacer las condiciones de la defensa afirmativa de la Rule 10b5-1(c).
La presentación muestra que, tras la venta, el Sr. Dambkowski poseía beneficiariamente 236,273 acciones, en propiedad directa. En este Form 4 no se informan transacciones con derivados: el documento se limita a la única venta no derivada y a la posición de propiedad relacionada.
Carl Dambkowski, Apogee Therapeutics(APGE) 최고의료책임자(Chief Medical Officer)는 08/06/2025에 Apogee 보통주 2,725주를 주당 보고가격 $37.78에 매도했다고 보고했습니다. 해당 거래는 Form 4에 기재되었으며, August 21, 2024에 채택된 Rule 10b5-1 거래계획에 따라 실행되었고, 제출서에는 이 계획이 Rule 10b5-1(c)의 적극적 방어(affirmative defense) 요건을 충족하기 위한 것이라고 설명되어 있습니다.
신고에 따르면 해당 매도 후 Dambkowski 씨는 직접 보유 형태로 236,273주를 실질적으로 보유하고 있었습니다. 이 Form 4에는 파생상품 거래가 보고되어 있지 않으며, 문서는 단일 비파생 매도 건과 관련 소유지분만을 다룹니다.
Carl Dambkowski, Chief Medical Officer d’Apogee Therapeutics (APGE), a déclaré la vente de 2,725 actions ordinaires d’Apogee le 08/06/2025 au prix déclaré de $37.78 par action. La transaction est enregistrée dans un Form 4 et a été exécutée conformément à un plan de négociation Rule 10b5-1 adopté le August 21, 2024, plan décrit dans le dossier comme destiné à satisfaire les conditions de la défense affirmative prévues par la Rule 10b5-1(c).
La déclaration indique qu’après la vente, M. Dambkowski détenait à titre bénéficiaire 236,273 actions, détenues directement. Aucune opération sur dérivés n’est signalée dans ce Form 4; le document se limite à cette seule vente non dérivée et à la position de détention correspondante.
Carl Dambkowski, Chief Medical Officer von Apogee Therapeutics (APGE), meldete den Verkauf von 2,725 Stammaktien von Apogee am 08/06/2025 zu einem gemeldeten Preis von $37.78 je Aktie. Die Transaktion ist in einem Form 4 aufgezeichnet und wurde gemäß einem Rule 10b5-1-Handelsplan ausgeführt, der am August 21, 2024 angenommen wurde; die Einreichung beschreibt den Plan als dazu bestimmt, die Voraussetzungen der sogenannten affirmative defense nach Rule 10b5-1(c) zu erfüllen.
Aus der Meldung geht hervor, dass Herr Dambkowski nach dem gemeldeten Verkauf 236,273 Aktien direkt besitzt. In diesem Form 4 sind keine Derivatgeschäfte angegeben; das Dokument beschränkt sich auf den einzelnen nicht-derivativen Verkauf und die damit verbundene Besitzposition.
- Transaction executed under a Rule 10b5-1 trading plan, showing the sale was part of a pre-established plan adopted on August 21, 2024.
- Substantial remaining ownership is reported: 236,273 shares beneficially owned following the transaction, held directly.
- Insider disposition reported: the Chief Medical Officer sold 2,725 shares on 08/06/2025 at $37.78 per share.
Insights
TL;DR CMO sold 2,725 shares under a pre-established 10b5-1 plan; ownership remains at 236,273 shares, a routine disclosure.
The Form 4 documents a single non-derivative sale of 2,725 shares at $37.78 executed under a Rule 10b5-1 plan adopted on August 21, 2024. Because the trade was carried out pursuant to a pre-existing plan, it reduces the likelihood that this sale reflects new, material company information. The filing also reports a direct beneficial ownership of 236,273 shares after the transaction, which retains an explicit ownership stake by the reporting officer. Impact to investors is informational; no derivatives or additional transactions were disclosed.
TL;DR Insider sale executed under a documented 10b5-1 plan; disclosure aligns with standard governance practice and enhances transparency.
The Form 4 specifies that the sale was made pursuant to a Rule 10b5-1 trading plan, which the filing states was adopted on August 21, 2024. Use of a documented trading plan and the timely Form 4 disclosure are consistent with accepted governance and insider-trading compliance practices. The report notes only a single non-derivative disposition and confirms direct beneficial ownership of 236,273 shares after the sale. From a governance perspective, the filing provides clear, itemized disclosure of the transaction and remaining ownership.
Carl Dambkowski, Chief Medical Officer di Apogee Therapeutics (APGE), ha segnalato la vendita di 2,725 azioni ordinarie di Apogee in data 08/06/2025 al prezzo indicato di $37.78 per azione. La transazione è riportata in un Form 4 ed è stata eseguita ai sensi di un piano di negoziazione Rule 10b5-1 adottato il August 21, 2024, descritto nel documento come finalizzato a soddisfare le condizioni della difesa affermativa previste dalla Rule 10b5-1(c).
Dalla comunicazione risulta che, dopo la vendita, il sig. Dambkowski possedeva beneficiariamente 236,273 azioni, detenute direttamente. Nel Form 4 non sono segnalate operazioni su derivati: il documento si limita a questa singola vendita non derivata e alla relativa posizione di proprietà.
Carl Dambkowski, Chief Medical Officer de Apogee Therapeutics (APGE), informó la venta de 2,725 acciones ordinarias de Apogee el 08/06/2025 a un precio informado de $37.78 por acción. La operación consta en un Form 4 y se ejecutó en virtud de un plan de negociación bajo la Rule 10b5-1 adoptado el August 21, 2024, descrito en la presentación como destinado a satisfacer las condiciones de la defensa afirmativa de la Rule 10b5-1(c).
La presentación muestra que, tras la venta, el Sr. Dambkowski poseía beneficiariamente 236,273 acciones, en propiedad directa. En este Form 4 no se informan transacciones con derivados: el documento se limita a la única venta no derivada y a la posición de propiedad relacionada.
Carl Dambkowski, Apogee Therapeutics(APGE) 최고의료책임자(Chief Medical Officer)는 08/06/2025에 Apogee 보통주 2,725주를 주당 보고가격 $37.78에 매도했다고 보고했습니다. 해당 거래는 Form 4에 기재되었으며, August 21, 2024에 채택된 Rule 10b5-1 거래계획에 따라 실행되었고, 제출서에는 이 계획이 Rule 10b5-1(c)의 적극적 방어(affirmative defense) 요건을 충족하기 위한 것이라고 설명되어 있습니다.
신고에 따르면 해당 매도 후 Dambkowski 씨는 직접 보유 형태로 236,273주를 실질적으로 보유하고 있었습니다. 이 Form 4에는 파생상품 거래가 보고되어 있지 않으며, 문서는 단일 비파생 매도 건과 관련 소유지분만을 다룹니다.
Carl Dambkowski, Chief Medical Officer d’Apogee Therapeutics (APGE), a déclaré la vente de 2,725 actions ordinaires d’Apogee le 08/06/2025 au prix déclaré de $37.78 par action. La transaction est enregistrée dans un Form 4 et a été exécutée conformément à un plan de négociation Rule 10b5-1 adopté le August 21, 2024, plan décrit dans le dossier comme destiné à satisfaire les conditions de la défense affirmative prévues par la Rule 10b5-1(c).
La déclaration indique qu’après la vente, M. Dambkowski détenait à titre bénéficiaire 236,273 actions, détenues directement. Aucune opération sur dérivés n’est signalée dans ce Form 4; le document se limite à cette seule vente non dérivée et à la position de détention correspondante.
Carl Dambkowski, Chief Medical Officer von Apogee Therapeutics (APGE), meldete den Verkauf von 2,725 Stammaktien von Apogee am 08/06/2025 zu einem gemeldeten Preis von $37.78 je Aktie. Die Transaktion ist in einem Form 4 aufgezeichnet und wurde gemäß einem Rule 10b5-1-Handelsplan ausgeführt, der am August 21, 2024 angenommen wurde; die Einreichung beschreibt den Plan als dazu bestimmt, die Voraussetzungen der sogenannten affirmative defense nach Rule 10b5-1(c) zu erfüllen.
Aus der Meldung geht hervor, dass Herr Dambkowski nach dem gemeldeten Verkauf 236,273 Aktien direkt besitzt. In diesem Form 4 sind keine Derivatgeschäfte angegeben; das Dokument beschränkt sich auf den einzelnen nicht-derivativen Verkauf und die damit verbundene Besitzposition.
FAQ
What transaction did Apogee (APGE) insider Carl Dambkowski report?
Was the sale by the APGE CMO part of a 10b5-1 plan?
How many Apogee shares does the reporting person own after the transaction?
Did the Form 4 report any derivative transactions for APGE?
What is the reporting person's role at Apogee?
Who signed the Form 4 filing for this transaction?
